Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 2
2008 1
2009 2
2010 2
2011 2
2012 1
2015 3
2016 1
2017 2
2018 3
2019 2
2020 4
2021 6
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.
Lewinsky H, Gunes EG, David K, Radomir L, Kramer MP, Pellegrino B, Perpinial M, Chen J, He TF, Mansour AG, Teng KY, Bhattacharya S, Caserta E, Troadec E, Lee P, Feng M, Keats J, Krishnan A, Rosenzweig M, Yu J, Caligiuri MA, Cohen Y, Shevetz O, Becker-Herman S, Pichiorri F, Rosen S, Shachar I. Lewinsky H, et al. Among authors: caserta e. JCI Insight. 2023 Jul 24;8(14):e173312. doi: 10.1172/jci.insight.173312. JCI Insight. 2023. PMID: 37485873 Free PMC article. No abstract available.
Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes.
Dona AA, Sanchez JF, Palmer JM, Synold TW, Chiuppesi F, Thomas S, Caserta E, Singer M, Tandoh T, Chowdhury A, Krishnan A, Rosenzweig M, Diamond DJ, Rosen S, Pichiorri F, Dadwal S. Dona AA, et al. Among authors: caserta e. J Immunol Sci. 2023;7(1):9-27. doi: 10.29245/2578-3009/2023/1.1241. Epub 2023 Jan 20. J Immunol Sci. 2023. PMID: 36996290 Free PMC article.
A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ-induced CD38 expression.
Murtadha M, Park M, Zhu Y, Caserta E, Napolitano O, Tandoh T, Moloudizargari M, Pozhitkov A, Singer M, Dona AA, Vahed H, Gonzalez A, Ly K, Ouyang C, Sanchez JF, Nigam L, Duplan A, Chowdhury A, Ghoda L, Li L, Zhang B, Krishnan A, Marcucci G, Williams JC, Pichiorri F. Murtadha M, et al. Among authors: caserta e. Blood. 2024 Apr 18;143(16):1599-1615. doi: 10.1182/blood.2023021570. Blood. 2024. PMID: 38394668
CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.
Lewinsky H, Gunes EG, David K, Radomir L, Kramer MP, Pellegrino B, Perpinial M, Chen J, He TF, Mansour AG, Teng KY, Bhattacharya S, Caserta E, Troadec E, Lee P, Feng M, Keats J, Krishnan A, Rosenzweig M, Yu J, Caligiuri MA, Cohen Y, Shevetz O, Becker-Herman S, Pichiorri F, Rosen S, Shachar I. Lewinsky H, et al. Among authors: caserta e. JCI Insight. 2021 Feb 22;6(4):e141683. doi: 10.1172/jci.insight.141683. JCI Insight. 2021. PMID: 33465053 Free PMC article.
Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.
Buettner R, Morales C, Caserta E, Troadec E, Gunes EG, Viola D, Khalife J, Li H, Keats JJ, Christofferson A, Wu X, Synold TW, Palmer J, Sanchez JF, Pozhitkov A, Vaidehi N, Marcucci G, Krishnan A, Rosenzweig MA, Pichiorri F, Rosen ST. Buettner R, et al. Among authors: caserta e. Blood Adv. 2019 Apr 9;3(7):1027-1032. doi: 10.1182/bloodadvances.2018027227. Blood Adv. 2019. PMID: 30940637 Free PMC article.
Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.
Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, Gunes EG, Sanchez J, McDonald T, Marcucci G, Kaur B, Rosenzweig M, Keats J, Rosen S, Krishnan A, Satoskar AR, Hofmeister CC, Pichiorri F. Ghose J, et al. Among authors: caserta e. Oncoimmunology. 2018 Jul 23;7(10):e1486948. doi: 10.1080/2162402X.2018.1486948. eCollection 2018. Oncoimmunology. 2018. PMID: 30288349 Free PMC article.
Leveraging IFNγ/CD38 regulation to unmask and target leukemia stem cells in acute myelogenous leukemia.
Murtadha M, Park M, Zhu Y, Caserta E, Dona AA, Singer M, Vahed H, Tasndoh T, Gonzalez A, Ly K, Sanchez JF, Chowdhury A, Pozhitkov A, Ghoda L, Li L, Zhang B, Krishnan A, Marcucci G, Williams J, Pichiorri F. Murtadha M, et al. Among authors: caserta e. bioRxiv [Preprint]. 2023 Mar 1:2023.02.27.530273. doi: 10.1101/2023.02.27.530273. bioRxiv. 2023. PMID: 36909542 Free PMC article. Preprint.
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, Ghoda L, Gunes EG, Sanchez JF, Khalife J, Martella M, Karanes C, Htut M, Wang X, Rosenzweig M, Chowdhury A, Sborov D, Miles RR, Yazaki PJ, Ebner T, Hofmeister CC, Forman SJ, Rosen ST, Marcucci G, Shively J, Keats JJ, Krishnan A, Pichiorri F. Viola D, et al. Among authors: caserta e. Leukemia. 2021 Jan;35(1):189-200. doi: 10.1038/s41375-020-0810-4. Epub 2020 Apr 16. Leukemia. 2021. PMID: 32296125 Free PMC article.
Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A, Nieves HC, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. Canella A, et al. Among authors: caserta e. Oncotarget. 2023 Sep 25;14:837-838. doi: 10.18632/oncotarget.28515. Oncotarget. 2023. PMID: 37747363 Free PMC article. No abstract available.
36 results